Myriad Genetics, Inc, a leader in genetic testing and precision medicine, announced a collaboration with Flatiron Health, a leading health tech company dedicated to expanding the possibilities of point of care solutions in oncology. This collaboration allows physicians to order Myriad’s MyRisk® Hereditary Cancer Test and view the results of the test directly in Flatiron’s cloud-based Electronic Medical Record (EMR) platform, OncoEMR®. MyRisk is the first hereditary cancer test to be incorporated into Flatiron’s OncoEMR.
The integration allows 4,200 providers at over 800 community-based cancer care locations across the U.S. in Flatiron’s network to conveniently order, receive, and review MyRisk testing results directly through their daily OncoEMR system. By creating a streamlined, end-to-end workflow for germline testing in OncoEMR, clinicians have access to the results they need at point-of-care, facilitating personalized treatment decisions for patients while reducing administrative burdens and improving turnaround times for results.
Also Read: Avacta Group Appoints Michelle Morrow, PhD as CSO
“Our collaboration with Flatiron integrates MyRisk testing with practicing clinicians’ current workflows, potentially enhancing access to and usability of germline testing for more personalized patient care,” said George Daneker Jr, MD, President and Chief Clinical Officer of Oncology, Myriad Genetics. “By making germline testing interoperable with OncoEMR, we aim to simplify the ordering experience for clinicians in Flatiron’s extensive network and provide important health information that may help improve patient care and outcomes. We look forward to expanding the availability of our other genomic testing solutions onto the OncoEMR platform in the future, addressing the needs of even more patients.”
“As we continue to advance personalized medicine, the importance of germline testing at the point of care is critical to improving patient outcomes,” said Stephen Speicher, MD, Senior Medical Director, Head of Clinical Oncology and Patient Safety at Flatiron Health. “By giving physicians the ability to order Myriad’s MyRisk Hereditary Cancer Test and to view the results directly within OncoEMR, we’re offering clinicians a seamless way to access the information they need to practice precision medicine, facilitating better patient outcomes, more time with patients, and a better care experience for physicians and their patients.”
SOURCE: GlobeNewswire